Skip to main content
. 2016 Aug 2;4(3):27. doi: 10.3390/vaccines4030027

Figure 3.

Figure 3

Comparison of the HCV-specific T-cell response in ChAd3-NSmut/MVA-NSmut vs. ChAd3-NSmut/Ad6-NSmut vaccinated HC- infected patients: (A) Aa comparison of the peak ex vivo IFNγ ELISpot response to HCV NS (sum of positive pools) in PEG-IFNα/rib treated (circles) or untreated (triangles) HCV infected patients after ChAd3-NSmut prime vaccination (open symbols), and after Ad6-NSmut (black) or MVA-NSmut (red) boost vaccination, and at the end of the study after Ad6-NSmut or MVA-NSmut boost vaccination (Kuskal-wallis unpaired multiple comparisons ANOVA with Dunn’s correction comparing within each time point p > 0.05); (B) the T-cell response to peptide pools covering the regions of HCV not included in the vaccine immunogen (Core, E1, E2, p7 and NS2; genotype 1b J4 sequence) tested in parallel in patients vaccinated with ChAd3-NSmut/Ad6-NSmut (black) or ChAd3-NSmut/MVA-NSmut (red; Friemand’s paired multiple comparisons ANOVA with Dunn’s correction for ChAd3/Ad6 and for ChAd3/MVA vaccine arms, p > 0.05); (C) a comparison of the peak breadth of the T-cell response in patients (circles) and healthy volunteers (stars) receiving ChAd3-NSmut/MVA-NSmut (red) or ChAd3-NSmut/Ad6-NSmut (black)—defined as the maximum number of positive pools (out of six pools tested; labelled F M; see Section 2.4) at any time during the vaccine trial. Bar at median. Kuskal-Wallis unpaired multiple comparison ANOVA with Dunn’s correction was applied.